{"commentary":{"count":45,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":25,"podcast":10,"youtube":9,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05176483\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"STELLAR-002","nct_id":"NCT05176483","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stellar-002-nct05176483. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"STELLAR-002","arms":[{"description":"Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the \"rolling 6\" design.","label":"Zanzalintinib + Nivolumab Dose-Escalation Cohorts","type":"EXPERIMENTAL"},{"description":"Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the \"rolling 6\" design.","label":"Zanzalintinib + Nivolumab + Ipilimumab Dose-Escalation Cohorts","type":"EXPERIMENTAL"},{"description":"The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.","label":"Zanzalintinib + Nivolumab Expansion Cohorts","type":"EXPERIMENTAL"},{"description":"The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.","label":"Zanzalintinib + Nivolumab + Ipilimumab Expansion Cohorts","type":"EXPERIMENTAL"},{"description":null,"label":"Zanzalintinib Single-Agent Expansion Cohorts","type":"EXPERIMENTAL"},{"description":"Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the \"rolling 6\" design.","label":"Zanzalintinib + Nivolumab + Relatlimab Dose-Escalation Cohorts","type":"EXPERIMENTAL"},{"description":"The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.","label":"Zanzalintinib + Nivolumab + Relatlimab Expansion Cohorts","type":"EXPERIMENTAL"},{"description":"Participants with mCRPC, post-androgen receptor pathway inhibitor (post-ARPI), visceral metastases. The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.","label":"Zanzalintinib + Docetaxel + Prednisone Dose Expansion Cohort","type":"EXPERIMENTAL"},{"description":"Participants in the DDI Cohort. The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.","label":"Zanzalintinib + DDI Probe Substrates Dose Expansion Cohort","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-06-28","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma (RCC)","Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Urothelial Carcinoma (UC)","Solid Tumor","Hepatocellular Carcinoma (HCC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","Drug-Drug Interaction (DDI)"],"enrollment":{"count":1394,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zanzalintinib","type":"DRUG"},{"name":"Nivolumab","type":"DRUG"},{"name":"Ipilimumab","type":"DRUG"},{"name":"Nivolumab + Relatlimab","type":"DRUG"},{"name":"Prednisone","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"},{"name":"DDI Probe Cocktail","type":"DRUG"}],"last_update":"2026-10-01","lead_sponsor":"Exelixis","official_title":"A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)","timeFrame":"Up to 36 months"},{"measure":"Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR)","timeFrame":"Up to 24 months"},{"measure":"Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS)","timeFrame":"Up to 24 months"},{"measure":"Expansion Stage Cohort 10 (CRC): Overall Survival (OS)","timeFrame":"6 months"},{"measure":"Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS)","timeFrame":"6 months"},{"measure":"Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without Zanzalintinib","timeFrame":"Predose upto 8 hours postdose"},{"measure":"Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without Zanzalintinib","timeFrame":"Predose upto 8 hours postdose"}],"references":[],"start_date":{"date":"2021-12-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05176483"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stellar-002-nct05176483"}